GlobalData on MSN
Actinogen treats first patient in XanaMIA trial for Alzheimer’s
Actinogen anticipates final topline efficacy and safety results for the full 36-week treatment period in November 2026.
Biological agents targeting interleukin-4 receptor alpha (IL-4Rα) in atopic dermatitis (AD) achieved rapid and substantial ...
Tom Nolan reviews this week’s research The bleeding risk in people taking apixaban was substantially lower than that of ...
According to The Boston Globe, HabitWorks serves up short, personalized scenarios and awards points when users choose more ...
Continuous wireless monitoring reduced in-hospital complications and mortality in an Italian pilot trial and significantly ...
A device designed to capture more TAVR procedural debris proves noninferior to an existing device in a large trial, but the ...
Newborn resuscitation training (NRT) programmes may decrease newborn deaths in the first 28 days after birth, mainly during the first 24 hours and the first 7 days after birth. Studies are still ...
The controversial findings had interventional cardiologists looking for answers, with operator experience coming into focus.
The biggest names in cardiology tech gathered in New Orleans for the American College of Cardiology (ACC) Scientific Sessions ...
AI Assistant Helps Recently Hospitalized Patients with Heart Failure Diagnosis Dr. Dean Kereiakes Dean Kereiakes, MD, FACC, MSCAI, and Chairman of The Christ Hospital Heart & Vascular Institute Dr.
GlyphAgo achieved therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations and reduce or ...
Study will explore early detection of atrial fibrillation to reduce stroke and heart failure risk through home blood pressure monitoringKYOTO, Japan, Apr 2, 2026 - (JCN Newswire) - OMRON Healthcare Co ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results